QIAGEN N.V. QGEN recently launched QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery.

The latest development will strongly boost the QIAGEN Digital Insights (“QDI”) bioinformatics business of the Genomics / NGS product group.

News in Detail

QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources. It identifies and extracts causal relationships between genes, diseases, drugs and other biological entities with AI, generating more than 600 million more biomedical relationships than its complement, QIAGEN Biomedical KB-HD. This expansive knowledge base helps data scientists understand disease mechanisms, identify drug targets or biomarkers and explore strategies for repurposing existing drugs.

Image Source: Zacks Investment Research

While QIAGEN Biomedical KB-HD is manually curated and known for its high quality and accuracy, QIAGEN Biomedical KB-AI contains more than 25 times more relationships, allowing data scientists to generate new insights. Both knowledge bases can be used to provide both high-quality and high-quantity biomedical relationship data for data scientists and bioinformaticians to mine and validate.

The key features of QIAGEN Biomedical KB-AI also include structured results in an ontology for rapid querying, advanced analytics and quarterly updates to capture the most recent research and discoveries. By combining the strengths of AI and human curation approaches, QIAGEN Biomedical KB-AI signifies a major step forward in the company’s mission to empower biopharma customers with the most comprehensive and informative molecular knowledge bases.

Industry Prospects

Per a Research report, the global drug discovery market was valued at $55.46 billion in 2022 and is expected to witness a CAGR of 9.2% up to 2032.

Other Developments in the QDI Business

In January 2024, QIAGEN announced an enhanced CLC Genomics Workbench Premium with LightSpeed technology, which supports next-generation sequencing for somatic cancer secondary analysis. Having launched last year for germline applications, including whole genome sequencing, whole-exome sequencing and large panel sequencing data, the new capabilities enable small and large labs to significantly reduce turnaround time in oncology testing by removing key barriers in the analysis cost and speed.